ClinicalTrials.gg
RecruitingNCT07863388Updated Nov 6, 2026

Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy

An interventional study of Autologous Platelet Rich Plasma and saline solution (placebo) in Erectile Dysfunction Following Radical Prostatectomy and Erectile Dysfunction, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Open to male participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Erectile Dysfunction with a site in Denmark — 2 open to participants now, 3 under way, none of them phase 3. Erectile Dysfunction · Denmark.

Planned enrollment
4th of 14
100 · median 90
Started
2026
the only one that year
No phase
9 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
5 of 18
Herlev and Gentofte Hospital

Among the 18 studies in Erectile Dysfunction with a site in Denmark, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 18th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

2 of the 18 studies in Erectile Dysfunction with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 40 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Erectile Dysfunction with a site in Denmark, or all of them as a file.
02

Study summary

This study will test whether injections of platelet-rich plasma (PRP) can improve erectile function in men with persistent erectile dysfunction (ED) at least 12 months after nerve-sparing radical prostatectomy for prostate cancer. Participants will be randomly assigned to receive either two PRP injections or two saline (placebo) injections into the penis, administered one month apart in a double-blind fashion. Erectile function will be assessed using the International Index of Erectile Function (IIEF) questionnaire at baseline and at 1, 3, 6, and 12 months after the last injection. The primary objective is to determine whether PRP improves the erectile function domain of the IIEF more than saline at one month after the last injection

Read the detailed description

Erectile dysfunction is common after nerve-sparing radical prostatectomy and may persist despite recovery from the initial nerve injury. Platelet-rich plasma (PRP) is prepared from autologous blood and contains growth factors that may promote angiogenesis and tissue regeneration. Preclinical studies suggest that PRP may improve erectile function after cavernous nerve injury, but PRP remains an experimental treatment, and no published study has specifically evaluated its effect in men with erectile dysfunction following radical prostatectomy.

The hypothesis is that intracavernosal PRP injections improve erectile function more than saline injections in men with erectile dysfunction persisting 1-3 years after nerve-sparing radical prostatectomy.

Eligible participants will be stratified according to unilateral or bilateral nerve-sparing surgery and randomized 1:1 to receive two intracavernosal injections of either autologous PRP or saline, administered one month apart. An unblinded team member who has no direct interaction with participants will prepare the injections. The participant and the physician administering the injection will remain blinded to treatment allocation. Syringes will be covered with opaque material to maintain blinding.

Blood will be collected before each injection in all participants. For participants assigned to PRP, the blood will be used to prepare the treatment. For the first 10 participants assigned to saline, PRP will also be prepared and analysed to verify the platelet concentration achieved with the preparation procedure. Blood collected from the remaining participants assigned to saline will be discarded.

Participants must discontinue other treatments for erectile dysfunction for four weeks before baseline and until the assessment one month after the last injection. Thereafter, other treatments for erectile dysfunction will be permitted and recorded.

Erectile function and other study outcomes will be assessed at baseline and at 1, 3, 6, and 12 months after the last injection. The primary outcome is the between-group difference in change from baseline in the erectile function domain of the International Index of Erectile Function at one month after the last injection.

03

Conditions studied

  • Erectile Dysfunction Following Radical Prostatectomy
  • Erectile Dysfunction

Keywords

  • Radical Prostatectomy
  • Erectile Dysfunction
  • Penile Rehabilitation
  • Nerve-Sparing Surgery
  • PRP
  • Male Urogenital Diseases
  • Platelet-rich plasma
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-75 years
  • Underwent unilateral or bilateral nerve-sparing radical prostatectomy between 1 and 3 years prior to the study
  • Good erectile function prior to surgery (IIEF-EF score ≥ 22)
  • Erectile dysfunction at inclusion with an IIEF-EF score \< 22 without aids
  • Acceptance of a pause in other treatments for erectile dysfunction from 4 weeks before baseline (wash-out) until the 1-month follow-up after the last injection
  • In a stable relationship lasting at least 6 months with a desire for sexual activity
  • Able to understand and accept the study protocol

Exclusion criteria

Exclusion Criteria:

  • Known psychiatric, neurological and/or endocrinological disease requiring medication (including hypogonadism with total testosterone \<12 nmol/l).
  • Severe urinary incontinence preventing sexual activity (assessed by a physician at inclusion)
  • Clinical or biochemical recurrence of prostate cancer
  • Other surgery or radiation therapy in the pelvic region
  • Severe cardiac disease in the form of unstable angina, class >II heart failure, uncontrolled arrhythmia, or severe symptomatic and/or significant valvular disease
  • Use of anti-androgen medication
  • Peyronie's disease and/or previous episodes of priapism
  • Excessive alcohol consumption (more than 21 units per week)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Platelet Rich Plasma (PRP)

    A volume of 5 mL PRP will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections

    Other: Autologous Platelet Rich Plasma

  • Other
    Saline Solution (Placebo)

    A volume of 5 mL saline solution will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections.

    Other: saline solution (placebo)

Interventions

  • OtherAutologous Platelet Rich Plasma

    A volume of 5 mL PRP will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections

    Also known as: PRP, Platelet-Rich Plasma

  • Othersaline solution (placebo)

    A volume of 5 mL saline solution will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Change in IIEF-EF score from baseline to 1 month after the final treatment session

    Change in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) from baseline to 1 month after the final treatment session. The change in IIEF-EF score will be compared between the PRP and saline groups using an intention-to-treat analysis.

    Time frame: From baseline to 1 month post the last intervention

Secondary outcomes

  1. Change in IIEF-EF score at 1 month after the final treatment session - per-protocol analysis

    Change in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) from baseline to 1 month after the final treatment session. The change in IIEF-EF score will be compared between the PRP and saline groups using a per-protocol analysis.

    Time frame: From baseline to 1 month post the last intervention

  2. Change in IIEF-EF score at 3, 6, and 12 months after the final treatment session

    Change in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) from baseline to 3, 6, and 12 months after the final treatment session. Analyses will be performed using both intention-to-treat and per-protocol populations, comparing the PRP and saline groups.

    Time frame: From baseline to 12 months post the last intervention

  3. Analyses of participants achieving a clinically significant improvement in IIEF-EF score at 1, 3, 6, and 12 months

    Intention-to-treat and per-protocol analyses of the proportion of participants achieving clinically significant improvements in IIEF-EF at 1, 3, 6, and 12 months following the final treatment session with PRP or saline. Clinically significant improvement is defined according to Rosen et al. as an increase of 2 points for mild ED, 5 points for moderate ED, and 7 points for severe ED

    Time frame: From baseline to 12 months post the last intervention

  4. Change in IIEF domain scores at 1, 3, 6, and 12 months

    Changes in the remaining domains of the International Index of Erectile Function (IIEF): orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. As no minimum clinically important difference has been established for these domains, changes in domain scores will be analysed as continuous variables and compared between the PRP and saline groups.

    Time frame: From baseline to 12 months post the last intervention

  5. Participant satisfaction after treatment

    Subjective participant satisfaction following treatment, assessed using the Global Satisfaction Question. This analysis will be performed according to the intention-to-treat principle.

    Time frame: From baseline to 12 months post last intervention

  6. Use of additional treatments for erectile dysfunction

    Use of additional treatments for erectile dysfunction during the study period, including oral medication, intraurethral treatment, intracavernosal injections, vacuum erection devices, and penile implants. The use of additional treatments will be compared between the PRP and saline groups.

    Time frame: Until 12 months post last intervention.

  7. Treatment effect according to baseline severity of erectile dysfunction, evaluated by the International Index of Erectile Function-Erectile Function (IIEF-EF)

    Subgroup analyses of treatment effects according to severity of erectile dysfunction at baseline (International Index of Erectile Function-Erectile Function (IIEF-EF), recorded just before the first injection). These analyses will be considered exploratory and hypothesis-generating.

    Time frame: From baseline to 12 months post last intervention

  8. Adverse events following treatment

    Incidence and type of adverse events following PRP and saline injections during the study period. All adverse events will be recorded and described in the final study manuscript.

    Time frame: From baseline to 12 months post last intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 21 months is below that.

Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Nov 10, 2026was Oct 2026
Primary completionEst.
Aug 2028
CompletionEst.
Nov 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Department of Urology, Herlev and Gentofte Hospital is now Recruiting
Nov 6, 2026
Start date
Oct 15, 2026→Nov 10, 2026
Nov 6, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedTreatment effect according to baseline severity of erectile dysfunction, evaluated by the International Index of Erectile Function-Erectile Function (IIEF-EF)Time frame: From baseline to 12 months post last intervention
Nov 2, 2026
Title
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy: a Randomized Controlled Trial
Nov 2, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 4 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Department of Urology, Herlev and Gentofte Hospital is now Recruiting
    Start date Oct 15, 2026→Nov 10, 2026
  2. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  3. Nov 2, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedTreatment effect according to baseline severity of erectile dysfunction, evaluated by the International Index of Erectile Function-Erectile Function (IIEF-EF)Time frame: From baseline to 12 months post last intervention
    Title Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy: a Randomized Controlled Trial
    + 1 other change: responsible party
  4. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863388
Lead sponsor
Herlev and Gentofte Hospital
Responsible party
Mikkel Fode (Professor, Herlev and Gentofte Hospital) — Principal investigator
First posted
Oct 7, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Frederikke Bay Toft, MD
Contact
frederikke.bay.toft.01@regionh.dk
+4538689927
Mikkel Fode, MD, PhD
principal investigator · Herlev and Gentofte Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion